QbD-driven RP-HPLC method for novel chemo-herbal combination, in-silico, force degradation studies, and characterization of dual drug-loaded polymeric and lipidic nanocarriers

被引：0
作者：
Ankaj Kumar
Sandeep Jat
Pramod Kumar
Arvind Gulbake
机构：
[1] National Institute of Pharmaceutical Education and Research Guwahati,Department of Pharmaceutics
[2] National Institute of Pharmaceutical Education and Research Guwahati,Department of Pharmaceutical Analysis
来源：
Future Journal of Pharmaceutical Sciences | / 9卷
关键词：
Lenvatinib; Biochanin A; RP-HPLC; HRMS; PLGA NPs; Cubosomes; Zeneth; Design of experiment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The RP-HPLC method was developed for a multiple tyrosine kinase inhibitor (MTKI), lenvatinib (LTB), and an isoflavone called biochanin A (BCA), employing Box–Behnken design (BBD).A total of 41.17% and 70.58% degradants were quantified through experimental investigation (RP-HPLC and HRMS) for LTB and BCA in contrast to in silico predicted degradants.In-silico toxicity assessment for LTB, BCA, and their degradants explains the necessity of conducting degradation studies during drug development.Finally, the applications of the developed RP-HPLC method for the development of chemo-herbal drug nanocarriers (polymeric and lipidic) were studied.
引用
收藏
相关论文
共 128 条
  • [11] Zhu H(2022)Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy Mater Today Bio 18 1116-94
  • [12] Chen H(2020)Comparative study of intratracheal and oral gefitinib for the treatment of primary lung cancer Eur J Pharm Sci 20 371-4188
  • [13] Zeng X(2023)An insight on synergistic anti-cancer efficacy of biochanin A and sulforaphane combination against breast cancer Appl Biochem Biotechnol 123 11-476
  • [14] Zhang S(2016)Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells Sci Rep 180 106246-1674
  • [15] Zhao L(2017)Formulation and optimization of doxorubicin and biochanin A combinational liposomes for reversal of chemoresistance AAPS PharmSciTech 15 2830-670
  • [16] Peng X(2022)The natural isoflavone Biochanin-A synergizes 5-fluorouracil anticancer activity in vitro and in vivo in Ehrlich solid-phase carcinoma model Phytotherapy Res 83 1383-516
  • [17] Nishio M(2020)The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma Cancer Cell Int 99 430-undefined
  • [18] Horai T(2020)Biochanin A: a novel bioactive multifunctional compound from nature Sci Total Environ 46 219-undefined
  • [19] Horiike A(2022)Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells Process Biochem 168 106491-undefined
  • [20] Makker V(2022)Biochanin A as a modulator of the inflammatory response: an updated overview and therapeutic potential Pharmacol Res 415 89-undefined
12345678910